# Camonsertib

Source: https://onco.cc/drugs/camonsertib/  
OnCo record `camonsertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.

## Summary

Camonsertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Hoffmann-La Roche, in metastatic cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral serine/threonine kinase inhibitor
- Mechanism: A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.

## Sources

- ClinicalTrials.gov: trials of Camonsertib: https://clinicaltrials.gov/search?intr=Camonsertib

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)
- trials: [Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study](https://onco.cc/trials/nct04589845/)

---
JSON: https://onco.cc/api/v1/entities/camonsertib.json